Theralink Technologies (Theralink Technologies) EPS (Diluted) : $-0.00 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies EPS (Diluted)?

Theralink Technologies's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

Theralink Technologies's EPS (Basic) for the three months ended in Dec. 2023 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

Theralink Technologies's EPS without NRI for the three months ended in Dec. 2023 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 47.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 79.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 73.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Theralink Technologies's highest 3-Year average EPS without NRI Growth Rate was 93.50% per year. The lowest was -2190.90% per year. And the median was 38.80% per year.

Theralink Technologies EPS (Diluted) Historical Data

The historical data trend for Theralink Technologies's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies EPS (Diluted) Chart

Theralink Technologies Annual Data

Trend

Feb14

Feb15

Dec16

Dec17

Dec18

Dec19

Sep20

Sep21

Sep22

Sep23

EPS (Diluted)

Get a 7-Day Free Trial

-19.00

-0.06

-0.01

Theralink Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.01	-	-	-	-

Competitive Comparison of Theralink Technologies's EPS (Diluted)

For the Biotechnology subindustry, Theralink Technologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralink Technologies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's PE Ratio distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's PE Ratio falls into.

Theralink Technologies EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Theralink Technologies's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-30.908	-	0.039)	/	6151.500
	=	-0.01

Theralink Technologies's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-19.047	-	0)	/	6151.500
	=	-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

Theralink Technologies (OTCPK:THER) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Theralink Technologies EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralink Technologies (Theralink Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401

Website

https://www.theralink.com

Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.

Executives

Danica Holley	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz	director	15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors	director	1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin	director, officer: Chief Executive Officer	HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc	10 percent owner	1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett	officer: Chief Executive Officer	230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb	director	PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman	10 percent owner, officer: Chief Operating Officer-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme	director, 10 percent owner, officer: Global Operations GM-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman	director	C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: CFO & President	549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head	director, officer: Chief Executive Officer	6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817